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Abstract 
Background: Powerful antibody-based immunosuppression induction is now used routinely during organ 
transplantation, and may place patients at even higher risk of post-transplant cancer. 
Materials and Methods: Incidence of de-novo head and neck cancer was extracted from the records of 
1685 consecutive adult, deceased donor liver transplant recipients with a minimum 1-year follow-up from 
2001 to 2015. There were 121 patients positively identified as having developed de-novo head and neck 
cancer post-liver transplant. Records of these patients were analyzed to determine demographics, history 
of cancer pre-liver transplant, de-novo cancer type and location, treatment modalities, and alcohol and 
tobacco exposure.  
Results: Of the 121 patients who developed cancer of the head and neck (7%), there were 103 cutaneous 
(6%) and 25 non-cutaneous (1%). For non-cutaneous cancers, factors associated with increased risk of 
cancer included alcohol abuse (p<0.001), any smoking history (p=0.05), and increasing exposure to 
tobacco (p<0.01). Ten-year Cox regression patient survival demonstrates a survival disadvantage for 
patients who develop non-cutaneous cancer (p=0.06), but a survival advantage for patients who develop 
cutaneous cancer (p<0.01). 
Conclusions: The incidence and pattern of head and neck cancer in this population of liver transplant 
patients was similar to those published previously, suggesting that induction immunosuppression does not 
increase risk of these types of cancers. Long term survival was worse for patients with non-cutaneous 
cancers, but better for those with cutaneous cancers, though the reason is unclear. 
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Introduction 
 In solid organ transplant patients, there is increased risk for de novo malignancies related 
to chronic immunosuppression.1,2 In recent years, there is increased use of powerful antibody 
therapies which are employed to rapidly induce an immunosuppressed state at the time of 
transplant.3-5 Immunosuppression induction has become standard of care at many centers and 
may be associated with less rejection and improved graft survival.6 However, it has been 
suggested that augmenting post-transplant immunosuppression predisposes transplant recipients 
to an even greater risk of de novo malignancy. Transplant patients are known to have an 
increased risk for many types of tumors, especially dermatologic cancers frequently found in the 
head and neck region.7-15 
 One group of patients at particular risk for post-transplant cancer are liver transplant 
patients because of the high incidence of alcohol abuse and tobacco use among this population.16 
Chronic exposure to these noxious substances has led to several published reports.7,8,14 This 
study seeks to determine the incidence of head and neck cancer in a large population of liver 
transplant recipients who all received antibody-based immunosuppression induction. 
Demographic and behavioral factors associated with tumor formation will be determined.  
Further, the subtypes of identified cancers will be noted, along with therapies and long-term 
outcomes.  
Materials and Methods 
 This study is a retrospective review of deceased donor, orthotopic liver transplant patients 
at a single, large U.S. center over a 15-year time period (2001 to 2015). Minimum follow-up was 
1-year, with median death-censored follow-up time of 72 months. Extracted data came from the 
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comprehensive transplant recipient registry at our center, and individual written and electronic 
medical records. Recipient inclusion criteria included all transplant recipients age 18 years and 
older receiving a deceased donor liver allograft. Graft and patient survival data were collected 
from the transplant database which is updated on a regular basis. This database also includes 
laboratory values and significant medical events post-transplant for all transplant recipients. 
All patients were listed for transplantation according to standard procedures and 
protocols as established by our center and by the United Network for Organ Sharing (UNOS). 
Patients are transplanted at all centers according to their model for end-stage liver disease 
(MELD) score, which is calculated using the serum total bilirubin, international normalized ratio 
(INR) and serum creatinine. In patients receiving re-transplantation, the analysis included only 
data for the first transplant and all patients were listed only once in the final data set. All patients 
were included in the final survival analysis without any exclusions for extenuating circumstances 
such as unexpected death or graft loss unrelated to the allograft or the transplant procedure 
(intention to treat). Data collection included patient and donor demographics and etiology of 
liver disease. A large portion of this data had been collected previously and is maintained in a 
comprehensive transplant center registry.  
This study undertook a detailed review of the pre- and post-transplant medical records of 
all liver transplant recipients to determine the pre-transplant history of cancer as well as the post-
transplant de novo incidence of cancer. Transplant outcomes included de novo cancer incidence 
of any type, recurrence of hepatocellular carcinoma (HCC) in patients with HCC on liver explant 
pathology, overall patient survival, cancer free survival, and cause-specific mortality. All 
occurrences of cancer incidence or patient death were included in the final analysis regardless of 
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the etiology, circumstances or co-morbidities. There was no specific cancer surveillance protocol 
instituted for this study, but the prevailing standard of care is followed by our center.  Cancer 
therapies included standard of care according to the site and type of cancer. The original surgical 
and medical records were reviewed to determine procedures performed and therapies 
administered. 
The immunosuppression protocol at this center has been described previously and 
includes induction therapy with rabbit anti-thymocyte globulin and steroids, followed by 
standard maintenance with tacrolimus monotherapy.4,6  All patients received 3 doses of the 
antibody induction agent with a total dose of 6mg/kg. These doses are administered on post-
operative days 2, 4 and 6. Over half of the patients also received a single dose of rituximab, an 
anti-B-cell agent (150mg/m2). Rituximab was added to the induction protocol in an attempt to 
prevent donor specific antibody formation. Goal tacrolimus levels ranged from 6-10ng/dL, 
depending upon the baseline serum creatinine and underlying disease of the recipient.  The 
immunosuppression protocol was stable throughout the study period. Experienced transplant 
hepatologists follow all patients post-transplant and provide routine screening for breast, colon, 
prostate, and cervical cancer. Patients are instructed to have a thorough dermatologic exam once 
yearly by a medical professional as surveillance for skin cancer. Any diagnosis of de novo or 
recurrent cancer required tissue confirmation with reading by a pathologist.  
Statistical testing was performed on SPSS software (IBM SPSS Statistics Version 24, 
IBM Corporation, Armonk, New York, USA). Standard statistical testing was utilized for 
continuous and categorical variables, as indicated. The Cox proportional hazards model was 
constructed using a direct entry method. Co-variates were included in the final model for 
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variables with p-value <0.10. Retrospective analysis of data for liver transplant patients at our 
centers was reviewed and approved by the institutional review board of the Indiana University 
School of Medicine. 
Results 
 There were 1685 patients who met inclusion criteria and had complete data for analysis. 
Median follow up was 72 months, ranging from 12 to 185 months. Of these liver transplant 
recipients, 121 (7%) were found to have 128 head and neck cancers (25 non-cutaneous and 103 
cutaneous). [Table 1] Patients with de novo cutaneous cancers were more likely to be male, 
White, older and have a lower model for end stage liver disease (MELD) score (all with p-value 
<0.01). Patients with de novo non-cutaneous head and neck cancers were similar for all 
demographics except for body mass index (BMI), in which case the patients with tumor had a 
lower median BMI (p=0.02). The results for risk of any head and neck cancer mirrored those of 
the cutaneous cancer group.  In a bivariate stratified analysis of these factors, the rate of 
cutaneous head and neck cancer in males was twice that seen in females (p<0.01). [Table 2] 
Cutaneous cancers were only seen in White patients (p=0.001), with an increasing risk of this 
type of cancer with increasing age (p<0.001) and lower MELD score (p=0.01). Among patient 
with non-cutaneous head and neck cancer, there was no association with any of these factors. 
Again, the risk of any cancer mirrored those of the cutaneous cancer group.  
 Subgroup analysis was performed to assess the association between known risk factors 
for cancer and the incidence of head and neck cancer in this cohort. [Table 3] The incidence of 
cutaneous cancer was not associated with a history of known alcohol abuse, nor with a history of 
any previous cancer. There was no association between cutaneous cancer and any history of 
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smoking, but there was a higher incidence for those patients with greater than 40 pack-years of 
smoking (p<0.01). Non-cutaneous cancers were associated with alcohol abuse (72% versus 37% 
p<0.001) and any history of smoking (68% versus 51%, p=0.05), as well as a trend of increasing 
risk with increased total tobacco exposure (p=<0.01).  Patients with a history of any cancer 
before liver transplant are not at increased risk for head and neck cancer post-liver transplant. 
 A summary of head and neck cancer subtypes and locations is provided. [Table 4] For 
cutaneous cancers, there were 57 squamous cell (3%, SCC), 48 basal cell (3%, BCC) and 1 
basosquamous cancer (<1%, BSC). There were 5 patients with melanoma (<1%). The most 
commonly involved sites included the nose (25), cheek/mandible (22), ear (18), forehead (18), 
scalp (15) and the neck (15). Of the 5 patients with melanoma, 4 melanomas were found in the 
scalp (1), temple (1) and neck (2). One melanoma was treated at an outside provider, and specific 
facial location was unavailable. Treatment for all cutaneous cancer included either excision 
(97%) or cryotherapy (4%), or both. Of the 5 patients with melanoma, all underwent simple 
excision (two with sentinel lymph node sampling), and one required subsequent neck dissection. 
At the time of this manuscript, 15 patients with cutaneous head and neck cancer (alone) had died 
(15%), but only two of these deaths were directly related to the cancer (both were metastatic 
melanoma).  
For non-cutaneous cancers, there were 25 cases, most commonly found in the larynx (7), 
oral cavity (5), hypopharynx (5), and oropharynx (4). One patient was diagnosed simply with 
“throat cancer” at an outside facility, and died shortly thereafter with no other information 
available. Of the 24 non-cutaneous cancer patients with available records, 7 also had cutaneous 
cancers, of which 5 were squamous cell, 1 was basal cell, and 1 was both basal and squamous 
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cell carcinoma. Cancer type in these 24 patients included squamous cell (18), thyroid cancer (3), 
and “throat cancer” (2). More radical therapies were commonly performed for these cancers, 
including neck dissection (8), laryngectomy (5), flap surgery (4), parotidectomy (4), 
thyroidectomy (3), glossectomy (3), and auriculectomy (1). There were 13 patients who received 
chemotherapy (54%) and 18 who received radiation therapy (75%), while 12 received both 
chemo- and radiation therapy (50%). At the time of this manuscript, 11 of the 25 patients with 
non-cutaneous head and neck cancer had died (44%), all related to complications of their cancer. 
Cox regression analysis of 10-year patient survival was performed. For patients who 
developed non-cutaneous head and neck cancer, there was a decreased survival of 14% (66% 
versus 52%, p=0.06) when compared to all other liver transplant patients in the cohort. [Figure 
1b] However, for patients with cutaneous head and neck cancer, there was an increased survival 
of 15% (80% versus 65%, p<0.01). [Figure 1a] The significant covariates included in the 
regression model included recipient and donor age, MELD score, hepatitis C infection, donation 
after cardiac death donor, and year of transplant (p<0.05 for each). Because of the unexpected 
finding of improved survival in the group with cutaneous head and neck cancer, additional 
variables were tested in the model including gender, race and tobacco use. Each of these 
additional variables was found to be non-significant. 
Discussion 
 The incidence of head and neck cancer in this population of liver transplant patients who 
received antibody-based immunosuppression induction was similar to that reported in previous 
publications of head and neck cancer in immunosuppressed patients, which is higher than that of 
the general population.17-19 This finding supports the validity of the data from this study and 
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suggests that induction immunosuppression does not place patients at higher risk than other 
immunosuppressed transplant patients. Most studies addressing head and neck cancers in 
transplant patients report data collected in countries outside the United States (U.S.), where 
tumor registries are more easily cross-matched.7-11,13,14 The reported incidence of all head and 
neck cancers at most centers is 6-7%, while non-cutaneous head and neck cancers are 1%. U.S. 
reports show lower rates, but the identification of tumors is likely less complete.12,15  The data 
from the present study are similar to the non-U.S. results, with a thorough review of all patients 
and a median follow up time of 72 months.  
 There was no association between non-cutaneous head and neck cancer and patient 
demographics. For cutaneous cancers, male gender, White race, increasing age and lower MELD 
score were associated with cancer incidence.  However, this study did find an increased risk of 
both cutaneous and non-cutaneous cancers to be associated with increased tobacco exposure, and 
non-cutaneous cancers were associated with any tobacco use and with alcohol abuse. 
Unfortunately, sun exposure could not be assessed in this population. Again, these results 
validate the findings of this study, as these outcomes are similar to those previously reported. It 
is important to note that tobacco use and alcohol abuse are common in the liver transplant 
population. This fact places this particular population at higher risk for non-cutaneous head and 
neck cancers because of the combined risk of lifetime tobacco and alcohol exposure and 
immunosuppression.  
 A detailed multivariate survival analysis was performed. As expected, the small number 
of patients who developed non-cutaneous head and neck cancer did have lower survival at 10-
year. However, even this group of high risk patients achieved a 52% 10-year survival. This 
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finding could be contributed to close surveillance and early detection, allowing for aggressive 
therapy to optimize survival. The survival advantage among the 103 patients who developed 
cutaneous head and neck cancer is unexpected. Further analysis of this 15% survival advantage 
(p<0.01) did not uncover a group difference to account for the result. 
 The higher prevalence of malignancies in the post-transplant population is related to the 
loss of immunosurveillance that is so critical to preventing growth and progression of cancer 
cells in the human body. Induction immunosuppression rapidly achieves a more profound 
immunosuppressed state within a very short time period. However, over the period of several 
months, the initial induction resolves and the patient returns to a level of immunosuppression 
dictated only by the maintenance immunosuppression. Centers employing immunosuppression 
induction frequently maintain lower maintenance immunosuppression as the view the early post-
transplant period as the most critical to preventing rejection. De novo cancers occur months to 
years after transplant and may be affected more by the choice of maintenance 
immunosuppression rather than the use of an induction protocol. Results from this study suggest 
that in a large number of patients receiving early immunosuppression induction, the risk of head 
and neck cancer was similar to that seen in previous reports without induction.  
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Table 1. Patient demographics, with stratification by the incidence of post transplant cutaneous and 
non-cutaneous head and neck cancer. 
  
  Overall 
Any head and neck 
cancer p-value 
  
 
  Yes No 
  
Number † 1685 121 (7%) 1564 (93%) 
Recipient gender 
     Male 68% 79% 67% <0.01 
Recipient race 
        
     White 89% 98% 88% <0.01 
Recipient age† (years) 55 59 54 <0.001 
Recipient BMI† 28.1 27.6 28.1 0.36 
Recipient model for end-stage 
liver disease score (MELD) † 18 17 18 <0.01 
Retransplant  2% 2% 2% 0.91 
 
  
Any cutaneous head 
and neck cancer p-value 
Any non-cutaneous 
head and neck 
cancer p-value 
 
Yes No   Yes No   
Number † 103 (6%) 1582 (94%) 25 (1%) 1660 (99%) 
Recipient gender 
     Male 80% 67% <0.01 80% 67% 0.18 
Recipient race 
      
     White 100% 88% 0.001 88% 89% 0.26 
Recipient age† (years) 59 54 <0.001 54 55 0.70 
Recipient BMI† 28.3 28.1 0.79 25.5 28.1 0.02 
Recipient model for end-stage 
liver disease score (MELD) † 17 18 <0.01 15 18 0.10 
Retransplant  2% 2% 0.90 0% 2% 0.50 
† Values given as group median
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Table 2. Incidence of post transplant cutaneous and non-cutaneous head and neck cancer stratified by patient 
demographics. 
        
  
  
Any 
cutaneous 
head and 
neck 
cancer p-value   
Any non-
cutaneous 
head and 
neck cancer p-value 
Any head 
and neck 
cancer p-value 
Number † 103 (6%) 25 (1%) 
 
121 (7%) 
Recipient gender 
        
     Male 7.2% 0.01   1.8% 0.20 8.4% <0.01 
     Female 3.8%     0.9% 4.6%   
Recipient race 
        
     White 6.9% 0.001   1.5% 0.26 7.9% <0.01 
     Black 0.0%     2.9% 2.9%   
     Other 0.0%     0.0% 0.0%   
Recipient age (median) 
    
  
  
     < 30 years 0.0% <0.001   1.8% 0.95 1.8% <0.001 
     30 to 39 years 2.4%     1.2% 3.6%   
     40 to 49 years 1.6%     1.9% 3.0%   
     50 to 59 years 6.6%     1.3% 7.8%   
     60 years and older 10.0%     1.4% 10.6%   
Recipient BMI (median) 
    
  
  
     Less than 25.0 6.3% 0.61   2.5% 0.25 7.9% 0.79 
     25.0 to 29.9 5.8%     1.3% 6.9%   
     30.0 to 34.9 7.5%     0.9% 8.0%   
     35.0 and higher 4.9%     1.1% 6.0%   
Recipient MELD at transplant (median) 
    
  
  
     Less than 20 7.1% 0.01   1.8% 0.47 8.3% 0.01 
     20 to 29 6.5% 1.7% 7.7% 
     30 and higher 1.1% 0.5% 1.6% 
† Total cancer number may exceed patient number because of multiple cancers. 
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Table 3. Incidence of post-transplant head and neck cancers, stratified by patient history of  tobacco use and alcohol abuse, 
and previous history of other cancers. 
      
 
       
 Overall 
Any cutaneous 
head and neck 
cancer p-value 
Any non-
cutaneous head 
and neck cancer p-value 
Any head and 
neck cancer p-value 
All patients 1685 103 (6%)  25 (1%)  121 (7%)  
 
       
Documented alcohol abuse 
       
     Yes 607 (37%) 40 (39%) 0.71 18 (72%) <0.001 54 (45%) 0.08 
     No 1027 (63%) 63 (61%)  7 (28%)  67 (55%)  
 
       
Tobacco use 
       
     Never smoker 833 (49%) 52 (50%) 0.83 8 (32%) 0.05 56 (46%) 0.47 
     Ever smoker 852 (51%) 51 (50%)  17 (68%)  65 (54%)  
        
Estimated tobacco exposure 
(pack-years) 
 
      
     Zero 863 (51%) 56 (54%) <0.01 8 (32%) <0.01 61 (50%) 0.001 
     1 to 19  242 (14%) 5 (5%)  1 (4%)  6 (5%)  
     20 to 40  431 (26%) 26 (25%)  10 (40%)  34 (28%)  
     More than 40  149 (9%) 16 (16%)  6 (24%)  20 (17%)  
        
Pre-transplant history of any non-liver cancer 
     
     Yes 161 (10%) 14 (14%) 0.15 2 (8%) 0.79 16 (13%) 0.15 
     No 1524 (90%) 89 (86%)  23 (92%)  105 (87%)  
        
Pre-transplant history of non-cutaneous head and neck cancer 
    
     Yes 12 (1%) 0 (0%) 1.00 0 (0%) 1.00 0 (0%) 1.00 
     No 1673 (99%) 103 (100%) 2 (100%)  121 (100%)  
        
History of hepatocellular carcinoma       
     Yes 393 (23%) 26 (25%) 0.64 5 (20%) 0.69 29 (24%) 0.86 
     No 1292 (77%) 77 (75%)  20 (80%)  92 (76%)  
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Table 4. Head and neck cancers by location and type in 1685 liver transplant patients. † 
 
 
Overall BCC SCC Melanoma Basosquamous 
Number of patients (% overall) with 
cutaneous head and neck cancer 103 (6%) 48 (3%) 57 (3%) 4 (<1%) 1 (<1%) 
  
Locations of cutaneous cancers ‡ 
  
        Scalp 15 (1%) 6 11 1 0 
        Nose 25 (2%) 20 11 0 1 
        Cheek/Mandible 22 (1%) 9 15 0 0 
        Ear 18 (1%) 11 8 0 0 
        Eyelid 5 (<1%) 3 3 0 0 
        Chin 2 (<1%) 1 1 0 0 
        Forehead 18 (1%) 9 14 0 0 
        Temple 8 (<1%) 2 6 1 0 
        Lip 4 (<1%) 2 3 0 0 
        Neck 15 (1%) 6 9 2 0 
Number of patients (%) with non-cutaneous 
head and neck cancer 25 (1%) 
Locations of non-cutaneous cancers 
        Larynx 7 
        Sternocleidomastoid 1 
        Thryroid  2 
        Oral Cavity 5 
        Nasopharynx 0 
        Oropharynx 4 
        Hypopharynx 5 
        Salivary Gland 4 
† Total cancer number may exceed patient number because of multiple cancers. 
   ‡ 10 patients did not have a specified location listed for cutaneous cancer. 
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